A 24-person study of treatment-resistant melanoma reported median survival of 17.8 months.
Nanobiotix (Euronext: NANO, NASDAQ: NBTX) presented Phase 1 study results showing 41.7% ORR and 17.8-month median survival in 24 advanced melanoma patients treated with JNJ-1900 (NBTXR3) and immunotherapy. The treatment demonstrated an acceptable safety profile and potential immune activation, warranting further trials. Data were shared at the 2026 ESMO Congress.
How this was made
The 30-second read
Why it matters
The trial shows early signs of activity in a hard‑to‑treat melanoma population, potentially positioning NBTX as a differentiated immuno‑radiotherapy candidate.
Market read
First disclosure of meaningful efficacy in a niche melanoma cohort; likely to move the stock and influence the oncology biotech sector.
What to watch
Long‑term safety and regulatory pathway remain uncertain; market may price in risk of later‑stage failures.
Background
Nanobiotix presented Phase 1 expansion results for NBTXR3 (JNJ‑1900) combined with radiotherapy and checkpoint inhibitors at the 2026 ESMO Congress.
Ticker impact
Nanobiotix disclosed Phase 1 data showing 41.7% ORR and median overall survival of 17.8 months in anti‑PD‑1‑resistant melanoma.
potential upside as investors price in promising trial results
First‑time disclosure of meaningful efficacy signals for a late‑stage biotech; market typically reacts favorably to such data.
Market effects
strengthens the anti‑PD‑1 resistant melanoma pipeline and may boost related immuno‑oncology stocks.
European biotech sector could see modest gains.
Adds optimism to the broader cancer‑immunotherapy landscape.
Counterpoint
Data are from a small, single‑arm study; efficacy may not translate to larger trials.
Key entities
- CompanyNanobiotix
Late‑stage clinical biotech developing NBTXR3.
- ProductJNJ‑1900 (NBTXR3)
Functionalized hafnium oxide nanoparticle injected intratumorally.
